Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514499 · ClinicalTrials.gov registry record · NA
Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study
A NA study of BRCA1/2 Negative, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT02514499 is a NA study of BRCA1/2 Negative that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 350 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02514499, a NA study of BRCA1/2 Negative, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcomes, to inform the debate over utility, risks, and benefits of clinical incorporation of multiplex testing for breast cancer susceptibility.
Conditions Studied
Interventions
- OTHER Questionnaires
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514499
The ClinicalTrials.gov registry entry for NCT02514499 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BRCA1/2 Negative appearing as the primary indexed condition, and to 1 intervention - of which Questionnaires is the first listed.
NCT02514499 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02514499 about?
NCT02514499 is a clinical study titled "Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study". The overall goal of the proposed research is to evaluate the uptake of testing and longitudinal risks and benefits of multiplex testing for cancer susceptibility in BRCA1/2 negative patients. This model will inform the selection of the outcomes and potential mediators and moderators of these outcome...
What is the current status of trial NCT02514499?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2014-07. Estimated completion is 2018-10.
What conditions does trial NCT02514499 study?
This clinical trial studies the following conditions: BRCA1/2 Negative.
What interventions are being tested in trial NCT02514499?
The interventions under investigation include: Questionnaires (OTHER).
Who is sponsoring clinical trial NCT02514499?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02514499 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.